Skip to main content
. 2025 Mar 24;85(12):2288–2301. doi: 10.1158/0008-5472.CAN-24-3217

Figure 6.

Figure 6.

MCHA treatment is SL with erdafitinib in FGFR-mutant bladder cancer. A, Cell Counting Kit-8 assay revealed the cell viability of MGH-U3 cells treated with DMSO, 10 μmol/L MCHA, 100 nmol/L erdafitinib, or combined therapy for 96 hours. B, Colony formation assay in the indicated MGH-U3 cells treated with DMSO, 10 μmol/L MCHA, 100 nmol/L erdafitinib, or combined therapy. C, Cell Counting Kit-8 assay revealed the cell viability of MGH-U3 cells treated with DMSO, 100 nmol/L afatinib, 100 nmol/L erdafitinib, or combined therapy for 96 hours. D, Colony formation assay in the indicated MGH-U3 cells treated with DMSO, 100 nmol/L afatinib, 100 nmol/L erdafitinib, or combined therapy. E and F,In vivo growth curve (E) and representative of xenograft tumors (F) formed by subcutaneous injection of MGH-U3 cells into the right flanks of nude mice (5 × 106 cells per mouse; n = 6 for each group) treated with DMSO, 5 mg/kg MCHA, 15 mg/kg erdafitinib, or combinational treatment. G and H,In vivo growth curve (G) and representative of xenograft tumors (H) formed by subcutaneous injection of MGH-U3 cells into the right flanks of nude mice (5 × 106 cells per mouse; n = 6 for each group) treated with DMSO, 5 mg/kg afatinib, 15 mg/kg erdafitinib, or combinational treatment. I, IHC staining of Ki67 on WT MGH-U3 xenografts treated as in E. Scale bar, 50 μm. J, IHC staining of Ki67 on WT MGH-U3 xenografts treated as in G. Scale bar, 50 μm. Data are presented as the means ± SD from three independent experiments. ***, P < 0.001; ****, P < 0.0001 (Student t test).